Complement Inhibitors for Treatment of Geographic Atrophy and Advanced Nonexudative AMD
Potential exists to slow or prevent disease progression.
Private Equity Update for Retinal Physicians
Take careful consideration before deciding to move forward.
The Mechanism of the Bispecific Antibody Faricimab
Targeting VEGF-A and Ang2 has effect greater than targeting either alone.
Retinal Gene Therapies in Clinical Trials
A proliferation of clinical trials means hope for patients.
Gene Therapy Implications for Retina Specialists
Evolving endpoints, novel orphan disease treatment paradigms, and the dawn of precision medicine.
The Port Delivery System With Ranibizumab
A new treatment strategy for patients with nAMD enters a phase 3 clinical trial.
Prefilled Syringe Delivery of Intravitreal Anti-VEGF Medications
Advantages for patients and physicians.
SUBSPECIALTY NEWS: Angiogenesis meeting highlights, elevated IOP after intravitreal injection, and more.
By REHAN M. HUSSAIN, MD
FUTURE FILE: Early data on promising new treatments for retinal disease.
Highlighting innovative early-stage and preclinical concepts in retina
CODING Q&A: Challenges in Remote Screening of Diabetic Patients
Part 1 of 2: patient care and reimbursement.
CLINICAL TRIAL DOWNLOAD: Two-Year Brolucizumab Data
Results reinforce the drug’s potential.
RETINA CONVERSATIONS: A Conversation With Evangelos S. Gragoudas, MD
Ocular cancer, angiogenesis, PDT, and more.
NEW PRODUCT APPLICATIONS: The Newest Frontier in Microperimetry
CenterVue’s intuitive MAIA can track a variety of macular pathologies.